光明乳業(600597.SH):新萊特完成發行1.8億新西蘭元無抵押次級企業債券
格隆匯12月18日丨光明乳業(600597.SH)公佈,2019年12月5日,公司第六屆董事會第三十五次會議審議通過《關於新萊特發行無抵押次級企業債券項目的議案》。同意公司下屬子公司新西蘭新萊特乳業有限公司(以下簡稱“新萊特”)在新西蘭發行為期5年、固定利率的無抵押次級企業債券。
2019年12月18日,公司接到新萊特通知,本次債券發行已完成,債券代碼:SML010,發行規模1.8億新西蘭元,為期5年,固定年利率3.83%。資金用於歸還部分新萊特現有的銀行債務,並提供多樣化的資金來源,以支持新萊特的戰略發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.